Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Derya KIVRAK SALİM"'
Autor:
Mustafa Ozgur Arici, Derya Kivrak Salim, Murat Kocer, Ahmet Sukru Alparslan, Baris Rafet Karakas, Banu Ozturk
Publikováno v:
Medicina, Vol 60, Iss 11, p 1849 (2024)
Background and Objectives: Neoadjuvant chemotherapy (NAC) improves survival by increasing pathologic complete response (pCR). Blood-based indexes have been studied in breast cancer for predicting pCR and prognosis, but the results are conflicting. We
Externí odkaz:
https://doaj.org/article/b45c69d582824e2fac5e49087419ff1c
Autor:
Arif Hakan Onder, Banu Ozturk, Murat Kocer, Deniz Ozbay Gediz, Derya Kivrak Salim, Mustafa Yildiz, Selami Bayram, Sevil Goktas
Publikováno v:
Medicine Science, Vol 12, Iss 3, Pp 827-52 (2023)
The aim of this study is to determine the discrepancy and agreement between Eastern Cooperative Oncology Group Performance Status (ECOG-PS) scores evaluated by doctors and patients and examine the factors that influence the performance evaluation of
Externí odkaz:
https://doaj.org/article/69b5fb7a86fd46b99e2afca49d9a1cce
Autor:
Neslihan Özyurt, Ali Alkan, Burcu Gülbağcı, Mustafa Seyyar, Esra Aydın, Mustafa Şahbazlar, Mehmet Türker, Oğuzcan Kınıkoğlu, Tahir Yerlikaya, Gülhan Dinç, Ali Aytaç, Ziya Kalkan, Senar Ebinç, İlkay Gültürk, Merve Keskinkılıç, Zehra Sucuoğlu İşleyen, Dilek Çağlayan, Alper Türkel, Teoman Şakalar, Serhat Sekmek, Nilgün Yıldırım, Sinem Koçak, Kerem Okutur, Ahmet Özveren, Bengü Dursun, Sait Kitaplı, Orhan Önder Eren, İsmail Beypınar, İlhan Hacıbekiroğlu, Devrim Çabuk, Elanur Karaman, Ömer Acar, Semra Paydaş, Melek Karakurt Eryılmaz, Bilgin Demir, Zeynep Oruç, Mesut Yılmaz, Fatih Selçuk Biricik, Derya Kıvrak Salim, Özgür Tanrıverdi, Mutlu Doğan
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. The aim of the study was to evaluate the prognostic impact of Her2 status in early triple negative breast cancer(TNBC). In the study TNBC patients
Externí odkaz:
https://doaj.org/article/ce3cface4e834236bebf941d34a5f4df
Autor:
Arif Hakan ONDER, Derya KIVRAK SALİM, Mustafa KARACA, Selami BAYRAM, Armağan AYDIN, Sevil GÖKTAŞ, Murat KOÇER, Deniz ÖZBAY GEDİZ, Mustafa YILDIZ, Banu ÖZTÜRK
Publikováno v:
Volume: 44, Issue: 4 384-389
Cumhuriyet Tıp Dergisi
Cumhuriyet Medical Journal
Cumhuriyet Tıp Dergisi
Cumhuriyet Medical Journal
İntroduction and aim: Cancer affects people psychologically and organically. The emotional state of cancer patients is fragile and can be affected by many factors. We aimed to evaluate the effect of the Covid-19 pandemic on the mood and behavioral c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a899aeff6854bbc60d8d81c9244488d6
https://dergipark.org.tr/tr/pub/cmj/issue/74897/1210488
https://dergipark.org.tr/tr/pub/cmj/issue/74897/1210488
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522311678
Background Leukocytoclastic vasculitis (LCV) is a vasculitic inflammation against blood vessels. Various anticancer therapies can cause vasculitis, but capecitabine-induced LCV is an unusual entity. Here, we describe an LCV case associated with neoad
Autor:
Özlem Özdemir, Baha Zengel, Yaşar Yildiz, Basak Oyan Uluç, Devrim Cabuk, Ercan Ozden, Derya Kivrak Salim, Semra Paydas, Atakan Demir, Omer Diker, Kezban Nur Pilanci, Özlem Uysal Sönmez, Sezai Vatansever, Izzet Dogan, Ahmet Gulmez, Burcu Cakar, Pinar Gursoy, Mahmut Emre Yildirim, Murat Ayhan, Nuri Karadurmus, Musa Baris Aykan, Gökcen Tugba Cevik, Teoman Sakalar, Ilhan Hacibekiroglu, Burcu Belen Gülbagci, Murat Dincer, Duygu Bayir Garbioglu, Yasemin Kemal, Erdinc Nayir, Halil Taskaynatan, Mesut Yilmaz, Okan Avci, Murat Sari, Ezgi Coban, Muhammed Mustafa Atci, Selin Aktürk Esen, Tugba Akin Telli, Fatih Karatas, Ali Inal, Hacer Demir, Nurhan Onal Kalkan, Cengiz Yilmaz, Funda Tasli, Ahmet Alacacioglu
In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::934c684ccacc5bd283fae448009bb29f
https://hdl.handle.net/11454/77368
https://hdl.handle.net/11454/77368
Autor:
Elvina Almuradova, irem öner, Murat Ayhan, Emre Yekedüz, Esma Turkmen Bekmez, Devrim Cabuk, Ahmet Gulmez, miraç özen, Melike Ozcelik, elif şenocak taşçı, Murat Dincer, Turgut Kaçan, Özgecan Dülgar, Ozlem Ozdemir, Melek Karakurt Eryilmaz, Ozkan Alan, Hasan Cagri Yildirim, Ebru Cilbir, Berna Öksüzoğlu, Serdar Turhal, Tugba Basoglu, Nazan Demir, Naziye Ak, Yusuf Karakas, Mutlu Dogan, Deniz Tataroğlu Özyükseler, Ali Inal, Abdullah Sakin, çağlar ünal, Ilhan Hacibekiroglu, Gulhan Ipek Deniz, Perran Fulden Yumuk, Dilek Erdem, Mehmet Ali Nahit Sendur, Cihan Erol, Suayib Yalcin, nelihan doğan, Bulent Karabulut, Ercan Ozden, Abdilkerim Oyman, Ozlem Er, Semra Paydas, Derya Kivrak Salim, Asude Aksoy
PurposeNeoadjuvant chemotherapy(NACT) in gastroesophageal junction(GEJ) and gastric cancer(GC) was shown to improve survival in recent studies. We aimed to share our real-life experience of patients who received NACT in order to compare the efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6d1eb63553c52367c6638ae07976dfd
https://doi.org/10.21203/rs.3.rs-884239/v1
https://doi.org/10.21203/rs.3.rs-884239/v1
Autor:
Elif Şenocak Taşçı, Başak Oyan, Özlem Sönmez, Arda Ulaş Mutlu, Muhammed Mustafa Atcı, Abdullah Sakin, İrem Öner, Havva Yeşil Çınkır, Melek Karakurt Eryılmaz, Dilek Çağlayan, Onur Yazdan Balçık, Nail Paksoy, Senem Karabulut, Derya Kıvrak Salim, Cemil Bilir, Miraç Özen, Melike Özçelik, Ali Arıcan, Baran Akagündüz, Ali İnal, Dinçer Aydın, Leyla Özer, Ahmet Gülmez, Nazım Serdar Turhal, Selin Aktürk Esen, Efnan Algın, Sinem Akbaş, Yakup İriağaç, Teoman Şakalar, Çağlar Ünal, Özlem Er, Şaban Seçmeler, Mustafa Bozkurt
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background The optimal treatment for metastatic colorectal cancer (mCRC) after the second line is still controversial. Regorafenib has been the standard of care in this setting as it improved overall survival (OS) compared to placebo. In rea
Externí odkaz:
https://doaj.org/article/7d19cca4236d429b8424cc6bef6070f5
Autor:
Elif Şenocak Taşçi, Basak Oyan, Ozlem Sonmez, Arda Ulaş Mutlu, Muhammed Mustafa Atcı, Irem Oner, Havva Yesil Cinkir, Melek Karakurt Eryılmaz, Onur Yazdan Balçık, Nail Paksoy, Derya Kivrak Salim, Mirac Özen, Melike Ozcelik, Ali Arican, Ali Inal, Baran Akagunduz, Dinçer Aydın, Leyla Ozer, Nazim Serdar Turhal, Ahmet Gulmez
Publikováno v:
Journal of Clinical Oncology. 40:202-202
202 Background: The optimal treatment for metastatic colorectal cancer (mCRC) after the second line is still controversial. Regorafenib (Reg) revealed promising results by improving overall survival compared to best supportive care. However, in real-
Autor:
Fatma Yalçin Müsri, Betül Ünal, Hasan Şenol Coşkun, Derya Kivrak Salim, Melek Karakurt Eryilmaz, Hasan Mutlu
Publikováno v:
Journal of Cancer Research and Therapeutics, Vol 14, Iss 3, Pp 619-624 (2018)
Objective: Increased tumor-infiltrating lymphocytes (TILs) in breast carcinoma tissues is an independent predictive factor for pathologic complete response (pCR). The increased intratumoral and stromal TILs (sTILs) in breast cancer (BC) have signific